Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $86.69.

Several equities analysts have commented on RARE shares. Cantor Fitzgerald reissued an “overweight” rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Wells Fargo & Company boosted their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Barclays dropped their price target on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Finally, Wedbush raised their price objective on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $45.13 on Wednesday. Ultragenyx Pharmaceutical has a 1 year low of $37.02 and a 1 year high of $60.37. The stock has a market capitalization of $4.17 billion, a P/E ratio of -6.98 and a beta of 0.58. The company’s 50-day moving average is $53.80 and its 200 day moving average is $48.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. During the same quarter in the prior year, the company earned ($2.23) EPS. The business’s revenue was up 42.3% compared to the same quarter last year. Research analysts anticipate that Ultragenyx Pharmaceutical will post -6.21 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. The trade was a 0.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. The trade was a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,556 shares of company stock worth $1,515,967. 5.80% of the stock is owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Ultragenyx Pharmaceutical in the second quarter worth about $33,000. UMB Bank n.a. boosted its holdings in shares of Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 352 shares during the last quarter. True Wealth Design LLC bought a new stake in Ultragenyx Pharmaceutical during the third quarter valued at approximately $43,000. Values First Advisors Inc. purchased a new stake in Ultragenyx Pharmaceutical during the third quarter valued at approximately $56,000. Finally, Nomura Asset Management Co. Ltd. bought a new position in Ultragenyx Pharmaceutical in the third quarter worth approximately $93,000. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.